Valneva : Annonce de perspectives MT attractives
>EBITDA ajusté meilleur qu’attendu - L’EBITDA ajusté ressort à -65 M€, au-dessus du Css à -72 M€. Nous retenons 1/ un CA total (déjà publié) en baisse de 57% YoY à 154 M€ impacté par un effet de base défavorable puisque 2022 comprenait 280 M€ de revenus liés aux accords de fourniture de vaccins COVID-19 (les ventes de produits sont en hausse de 26% et 63% hors vaccins COVID) , 2/ une marge brute totale sur les ventes de produit stable à 46% vs 45.5% en 2022, mais en ...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.